#biotech

Last 24h 📈 Bullish 📈1

Last 7 Days 📈 Bullish 📈9 📉6 📊4

Last 30 Days 📈 Bullish 📈33 📉16 📊20

News 📈 Stocks

ORIC Pharmaceuticals Launches Phase 3 Prostate Cancer Trial With $387M Runway

September 15, 2026 (10 days ago)

ORIC Pharmaceuticals advances its clinical pipeline with a new Phase 3 prostate cancer trial, balancing a robust cash runway against significant share…

ORIC BAYN

🌍 AMERICAS Read More →

News 📈 Stocks

Geron Projects RYTELO Revenue at $240M High End Amid Community Expansion

September 15, 2026 (11 days ago)

Geron Corporation targets the high end of its 2026 revenue guidance as it shifts commercial focus toward community-based treatment settings and earlier…

GERN

🌍 AMERICAS Read More →

News 📈 Stocks

Definium Therapeutics Shares Rally 190% YTD on Positive Phase 2 LSD Trial Data

September 14, 2026 (11 days ago)

Definium Therapeutics shares climb as synthetic LSD treatment shows superior efficacy in Phase 2 anxiety trials, marking another milestone for the biotech…

DFTX

🌍 AMERICAS Read More →

News 📈 Stocks

Scholar Rock Shares Jump 9% Following FDA Approval of ISEMBYLD

September 14, 2026 (11 days ago)

Scholar Rock rallies 9% as FDA approval of its muscle-targeted therapy for spinal muscular atrophy prompts a wave of analyst price target…

SRRK SPX DJI +1

🌍 AMERICAS Read More →

News 📈 Stocks

Olema Shares Slide 15% as AstraZeneca Breast Cancer Trial Fails

September 14, 2026 (11 days ago)

Olema Pharmaceuticals shares fell 15.1% after AstraZeneca's camizestrant failed a key breast cancer trial, prompting Stifel to cut its price target on…

OLMA AZN

🌍 AMERICAS Read More →

IPO 📈 Stocks

Electra Therapeutics Targets $977.6 Million Valuation in Nasdaq IPO

September 14, 2026 (11 days ago)

Electra Therapeutics seeks a $977.6 million valuation as it joins a rebounding biotech IPO market, with plans to list on the Nasdaq…

ETRA

🌍 AMERICAS Read More →

News 📈 Stocks

Novartis Pelacarsen Trial Failure Triggers 10% Amgen Sell-Off

September 14, 2026 (11 days ago)

Novartis' failed cardiovascular trial for pelacarsen has roiled the biotech sector, causing a 10% drop in Amgen shares while Eli Lilly maintains…

NVS AMGN IONS +1

🌍 AMERICAS Read More →

News 📈 Stocks

Certara Reports Mixed Q2 2026 Results as Software Growth Battles Services Slump

September 14, 2026 (11 days ago)

Certara's Q2 results highlight a company in transition, balancing strong software momentum against a services slowdown and restructuring costs, while maintaining a…

CERT

🌍 AMERICAS Read More →

News 📈 Stocks

Hair-Loss Drug Stocks Rally 500% as Investors Bet on Next Pharma Goldmine

September 13, 2026 (13 days ago)

Veradermics and Absci lead a surge in hair-loss drug stocks, though clinical risks and the lack of insurance coverage for cosmetic treatments…

MANE ABSI

🌍 AMERICAS Read More →

News 📈 Stocks

Biogen Targets Growth Through Pipeline Diversification and Cost Management

September 12, 2026 (13 days ago)

Biogen pivots toward immunology and nephrology, leveraging 10 Phase III programs and cost-saving initiatives to drive long-term growth and offset legacy portfolio…

BIIB

🌍 AMERICAS Read More →

News 📈 Stocks

BioMarin and Ascendis Resolve Patent Dispute, Shares Rally 5% on Settlement

September 12, 2026 (13 days ago)

BioMarin and Ascendis settle a global patent dispute over the drug Yuviwel, with BioMarin securing a 20% US royalty stream and Ascendis…

BMRN ASND

🌍 GLOBAL Read More →

News 📈 Stocks

Renalytix Shares Rally 7% as UBS Increases Stake and CEO Buys Stock

September 12, 2026 (13 days ago)

Renalytix shares gained 7% after UBS increased its voting stake to 6.62% and CEO James McCullough purchased additional shares, bolstering confidence in…

RNLXY

🌍 AMERICAS Read More →